Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuhan YZY Biopharma CoHKSE:02496 EV-to-FCF is -29.94 as of Jul. 22, 2026. The stock has 8 warning signs investors should review. Among 337 Biotechnology companies, Wuhan YZY Biopharma Co ranks worse than 296735.61% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Wuhan YZY Biopharma Co's Enterprise Value is HK$747.25 Mil.
Wuhan YZY Biopharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-24.96 Mil. Therefore, Wuhan YZY Biopharma Co's EV-to-FCF for today is -29.94.
The historical rank and industry rank for Wuhan YZY Biopharma Co's EV-to-FCF or its related term are showing as below:
HKSE:02496'
s EV-to-FCF Range Over the Past 10 Years
Min: -62.71 Med: -12.6 Max: -7.49
Current: -29.94
During the past 5 years, the highest EV-to-FCF of Wuhan YZY Biopharma Co was -7.49. The lowest was -62.71. And the median was -12.60.
HKSE:02496's EV-to-FCF is ranked worse than 100% of 337
companies
in the Biotechnology industry
Industry Median: 15.15
vs HKSE:02496: -29.94
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Wuhan YZY Biopharma Co (HKSE:02496) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Wuhan YZY Biopharma Co's PE Ratio (TTM) for today is calculated as:
Wuhan YZY Biopharma Co's share price for today is HK$3.69.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Wuhan YZY Biopharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.483.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02496 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Wuhan YZY Biopharma Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan YZY Biopharma Co EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Wuhan YZY Biopharma Co's EV-to-FCF falls into.
Wuhan YZY Biopharma Co's current Enterprise Value is HK$747.25 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Wuhan YZY Biopharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-24.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan YZY Biopharma Co (HKSE:02496) has a EV-to-FCF of -29.94 as of Jul. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Wuhan YZY Biopharma Co and its competitors. According to the industry distribution chart, Wuhan YZY Biopharma Co ranks #999999 out of 337 companies in the Biotechnology industry.
Is Wuhan YZY Biopharma Co's EV-to-FCF too high?
Wuhan YZY Biopharma Co's current EV-to-FCF is -29.94. Based on the distribution chart, Wuhan YZY Biopharma Co ranks #999999 out of 337 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Wuhan YZY Biopharma Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Wuhan YZY Biopharma Co ranks #999999 out of 337 companies for EV-to-FCF. This places Wuhan YZY Biopharma Co in the lower half of its industry. The industry median EV-to-FCF is 15.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.15, based on 337 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Wuhan YZY Biopharma Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuhan YZY Biopharma Co's current EV-to-FCF is -29.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan YZY Biopharma Co stock overvalued right now?
Wuhan YZY Biopharma Co (HKSE:02496) has a current EV-to-FCF of -29.94. The current EV-to-FCF is -29.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Wuhan YZY Biopharma Co (HKSE:02496), the current EV-to-FCF is -29.94 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02496 has been successfully added to your 
